Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Agenus scales the AI ALPS

How Agenus’ machine learning platform helps pick combos for clinical testing

Agenus is using its artificial intelligence, machine learning platform to match cancer patients with the best monotherapy or combination therapy it has, and to uncover mechanisms of resistance to develop new therapies using non-responder data.

The platform, called ALPS (Adaptive Learning Platform Systems), combines patient data from Agenus’ clinical trials with preclinical data from

Read the full 535 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers